Poltreg (WAR:PTG) Current Deferred Revenue: zł0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:PTG Poltreg SA WAR:PTG
46 GF Score
Price zł21.90
GF Value zł14.20
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Poltreg Current Deferred Revenue?

Poltreg WAR:PTG -0.90% 46 Current Deferred Revenue is zł0.00 Mil as of Mar. 2026. GuruFocus rates WAR:PTG with a GF Score™ of 46/100 and a GF Value™ of zł14.20 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Poltreg's current deferred revenue for the quarter that ended in Mar. 2026 was zł0.00 Mil.

Poltreg Current Deferred Revenue Related Terms

Poltreg Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Poltreg's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poltreg Current Deferred Revenue Chart

Poltreg Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Poltreg Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:PTG
46GF Score
Poltreg SA WAR:PTG
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of zł0.00 Mil mean?
Poltreg (WAR:PTG) has a Current Deferred Revenue of zł0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Poltreg and its competitors.
Is Poltreg's Current Deferred Revenue too high?
Poltreg's current Current Deferred Revenue is zł0.00 Mil. Overall, Poltreg has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Poltreg's Current Deferred Revenue compare to VRTX and REGN?
Poltreg's Current Deferred Revenue of zł0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Poltreg and its competitors. Poltreg's current Current Deferred Revenue is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poltreg stock overvalued right now?
Based on GuruFocus' analysis, Poltreg (WAR:PTG) is currently considered Significantly Overvalued. The stock's GF Value™ is zł14.20, compared to a current price of zł21.90 — trading 54.2% above its estimated fair value. The current Current Deferred Revenue is zł0.00 Mil. Poltreg's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Poltreg (WAR:PTG), the current Current Deferred Revenue is zł0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poltreg (WAR:PTG) Overvalued in 2026?

Based on GuruFocus' analysis, Poltreg stock appears to be overvalued. The current stock price of zł21.90 is trading 54.2% above its estimated GF Value™ of zł14.20. GuruFocus considers Poltreg to be Significantly Overvalued.

Key valuation signals for WAR:PTG:

  • Current Deferred Revenue: zł0.00 Mil
  • GF Value™: zł14.20 vs. price of zł21.90 (54.2% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the WAR:PTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poltreg Business Description

Address ul.Botaniczna 20, Gdansk, POL, 80-298
Poltreg SA is a biotechnology company at the clinical stage developing an innovative generation of medicines using T-regulatory cells (TREGS) in the treatment of autoimmune diseases.
46GF Score

Get the complete analysis for WAR:PTG

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł21.90
Price
zł14.20
GF Value